Leader in clinical microbiology innovation
QuantaMatrix was founded in 2010 as an in-vitro diagnostics company. It is a spin-off from Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University led by Dr. Sunghoon Kwon, professor of Electrical and Computer Engineering Department at Seoul National University. We resolve antibiotics misuse issue and promote optimal antimicrobial prescription by providing direct Rapid Antimicrobial Susceptibility Test (dRASTTM) for treating sepsis. Sepsis is a life-threatening condition with mortality rate of more than 40% and every 1-hour delay in treatment increases mortality risk by seven to nine percent. In the U.S. alone, the annual socioeconomic cost is approximately $27 billion; therefore, the prescription of optimal antimicrobial is essential to preventing the progression of bacteremia to sepsis. Conventional antimicrobial susceptibility test (AST), which follows blood culture, pure culture, identification (ID), and susceptibility testing, takes over 60 hours, or three business days for hospitals to conduct. Minimizing the time to optimal treatment is directly linked to patient survival. dRASTTM, our rapid antimicrobial susceptibility test solution, decrease the time to optimal treatment by 30-50 hours. By decreasing the time of empirical treatment through dRASTTM, we can expect more effective treatment against bacterial infection and prevent antimicrobial resistance by reducing the prescription of inappropriate antibiotics. Moreover, the shortened treatment time improves the profitability of hospitals with shorter length of stay in hospital. Thus, dRASTTM possesses significant clinical and socioeconomic benefits. In our pipeline, we have competitive products such as QDSTTM, a rapid drug susceptibility test for Mycobacterium tuberculosis; QPLEXTM Alz plus assay, early detection of an Alzheimer's disease; or Quanti9TM & QuantiGalTM, a prognostic prediction kit for Cardiovascular diseases in research use only cases. We aim to continue our growth as the most innovative in vitro diagnostics company in fields of microbiology, molecular biology, and immunoassay.
QuantaMatrix's microbial diagnostics solutions are the first to be developed in Korea and have received the highest honors including the New Excellent Technology (NET) certification and new medical technology certification.